Related Experiment Videos
Amantadine for levodopa resistant parkinsonism.
The International Journal of Neuroscience
|February 1, 1987
Summary
Amantadine effectively treated Parkinsonism symptoms in a patient resistant to other therapies, improving both motor function and mental status. This case highlights amantadine as a potential therapeutic option for refractory Parkinsonism.
Area of Science:
- Neurology
- Pharmacology
Background:
- Parkinsonism is a complex neurological disorder characterized by motor and cognitive impairments.
- Standard treatments like levodopa, bromocriptine, and anticholinergics are not universally effective.
Observation:
- A 65-year-old female patient presented with symptoms indicative of Parkinsonism.
- This patient exhibited resistance to conventional therapeutic agents, including levodopa, bromocriptine, and anticholinergics.
Findings:
- Daily administration of amantadine (200 mg/day) resulted in significant amelioration of motor disability.
- Amantadine also led to notable improvements in the patient's mental status.
Implications:
- This case suggests amantadine may be a viable treatment for patients with Parkinsonism refractory to standard therapies.
- Further investigation into the mechanisms underlying amantadine's efficacy in such cases is warranted.